鶹ýӰ

Meeting Coverage

SGO

Society of Gynecologic Oncology

Lenvatinib-Pembrolizumab Combo Misses on Survival in Endometrial Cancer Trial

Combination in first-line fails to improve progression-free, overall survival versus chemotherapy

SGO over a photo of San Diego Convention Center in San Diego, CA

Latest SGO Meeting Coverage

Rucaparib Maintenance Boosts PFS in Metastatic, Recurrent Endometrial Cancer

Use of the PARP inhibitor improved PFS by 19.4 months versus placebo in phase II study

March 19, 2024
Safety of Less-Radical Surgery for Early Cervical Cancer Gathers More Evidence

Growing body of data suggest it can be safe and effective in low-risk disease, says expert

March 18, 2024
Novel Drug-Device Shows Efficacy for High-Grade Cervical Lesions

Response rate doubles with the noninvasive treatment versus placebo

March 18, 2024
Gynecologic Oncology May Face a Future of Too Few Cases, Too Many Docs

Subspecialists could see only one patient a week with a new cancer diagnosis, researcher says

March 18, 2024
Laparoscopy Quickly Abandoned in Early Cervical Cancer After LACC Results

MIS roughly halved in the 2 years following the study results, national dataset shows

March 18, 2024
Immune Checkpoint Inhibitor-Chemo Combo Boosts OS in Advanced Endometrial Cancer

Dostarlimab and pembrolizumab regimens should be incorporated into practice "as of yesterday"

March 17, 2024
Raludotatug Deruxtecan Promising in Platinum-Resistant Advanced Ovarian Cancer

Novel ADC targeting CDH6 achieves response in nearly 50% of patients

March 17, 2024
VTE Risk in Recurrent Ovarian Cancer Increases With More Lines of Chemotherapy

Prospective study in heavily treated population is warranted, researcher says

March 30, 2023
Obesity's Impact on Uterine Cancer Risk Greater in Younger Age Groups

Overall risk and risk of endometrioid subtype 20- to 30-fold greater in women younger than 35

March 30, 2023
Phase III Trials 'Hit a Home Run' in Advanced Endometrial Cancer

Adding immunotherapy will change frontline treatment, experts say

March 28, 2023
Novel Strategies Show Winning Potential in Ovarian Cancer

High response rates in small studies of immuno-oncology combination, neoadjuvant olaparib

March 28, 2023
No Survival Benefit With CRT Versus Chemo for Locally Advanced Endometrial Cancer

Long-running clinical trial failed to identify any subgroup that fared better with CRT

March 27, 2023
CRT Regimen Boosts Complete Response Rate in Unresectable Vulvar Cancer

Pathologic response rises to 73% versus 50% in historical control group

March 27, 2023
CDK4/6 Inhibition Active in Recurrent Low-Grade Serous Ovarian Cancer

Responses in a fourth of patients, clinical benefit in up to 90%

March 26, 2023